KRAS and lung adenocarcinoma: However, a multi-omics analysis uncovered the heterogeneity of KRAS-mutant lung adenocarcinomas based on co-occurring genetic alterations including inactivation of TP53 or LKB1 and low expression of the thyroid transcription factor-1 (TTF-1) [23,24].